KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Cash & Current Investments (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Cash & Current Investments data on record, last reported at $5.5 billion in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 39.12% year-over-year to $5.5 billion; the TTM value through Sep 2025 reached $8.4 billion, down 13.81%, while the annual FY2025 figure was $5.5 billion, 39.12% down from the prior year.
  • Cash & Current Investments reached $5.5 billion in Q4 2025 per REGN's latest filing, down from $8.4 billion in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $10.8 billion in Q4 2023 and bottomed at $3.5 billion in Q1 2021.
  • Average Cash & Current Investments over 5 years is $7.9 billion, with a median of $8.3 billion recorded in 2025.
  • Peak YoY movement for Cash & Current Investments: skyrocketed 101.23% in 2022, then plummeted 39.12% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $5.8 billion in 2021, then skyrocketed by 33.77% to $7.7 billion in 2022, then skyrocketed by 40.07% to $10.8 billion in 2023, then dropped by 16.9% to $9.0 billion in 2024, then tumbled by 39.12% to $5.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $5.5 billion in Q4 2025, $8.4 billion in Q3 2025, and $7.5 billion in Q2 2025.